Erez Vigodman - Teva Pharmaceutical CEO

TEVA Stock  ILA 5,244  98.00  1.90%   

CEO

Mr. Erez Vigodman serves as President, Chief Executive Officer and Director at Teva Pharmaceutical Industries Limited since February 11, 2014 after joining Tevas Board of Directors in 2009. From 2010 to 2014, he served as President and Chief Executive Officer of Adama Agricultural Solutions Ltd. . From 2001 to 2009, he served as President and Chief Executive Officer of Strauss Group Ltd. Mr. Vigodman is a member of the Advisory Committee to the Israel National Economic Council and the International Advisory Board of the Israel Science Technology Innovation Policy Institute. Mr. Vigodman received a Bachelors degree in Accounting and Economics from Tel Aviv University in 1987 and is a graduate of the program of Management Development at Harvard Graduate School of Business Administration. Mr. Vigodman is a certified public accountant. since 2014.
Age 55
Tenure 10 years
Phone(972) 3 914 8213
Webwww.tevapharm.com

Teva Pharmaceutical Management Efficiency

The company has return on total asset (ROA) of 0.0363 % which means that it generated a profit of $0.0363 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2414) %, meaning that it generated substantial loss on money invested by shareholders. Teva Pharmaceutical's management efficiency ratios could be used to measure how well Teva Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 19.1 B in total debt with debt to equity ratio (D/E) of 2.26, implying the company greatly relies on financing operations through barrowing. Teva Pharmaceutical has a current ratio of 0.99, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Teva Pharmaceutical until it has trouble settling it off, either with new capital or with free cash flow. So, Teva Pharmaceutical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Teva Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Teva to invest in growth at high rates of return. When we think about Teva Pharmaceutical's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

CEO Age

Yuval BronsteinAzrieli Group
47
Stella HandlerBezeq Israeli Telecommunication
55
Arnon TorenAzrieli Group
60
Eyal LapidotDelek Group
52
David MizrahiBezeq Israeli Telecommunication
53
Asaf BartfeldDelek Group
66
Mordechay ElmaliachBezeq Israeli Telecommunication
57
Ron EilonBezeq Israeli Telecommunication
52
Ran GuronBezeq Israeli Telecommunication
55
CecileEsther EldanDelek Group
63
Yosef AbuDelek Group
40
Doron TurgemanB Communications
49
Leslie ThomasDelek Group
60
Israel KerenAzrieli Group
76
Gil SharonBezeq Israeli Telecommunication
51
Shmuel AntzelDelek Group
57
Ami BarlevB Communications
40
Eyal ChenkinAzrieli Group
47
Eyal HankinAzrieli Group
N/A
Nathan HaitchookAlony Hetz Properties
65
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel. TEVA PHARMA is traded on Tel Aviv Stock Exchange in Israel. Teva Pharmaceutical Industries (TEVA) is traded on Tel Aviv Stock Exchange in Israel and employs 34,004 people.

Management Performance

Teva Pharmaceutical Leadership Team

Elected by the shareholders, the Teva Pharmaceutical's board of directors comprises two types of representatives: Teva Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Teva. The board's role is to monitor Teva Pharmaceutical's management team and ensure that shareholders' interests are well served. Teva Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Teva Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Moshe Many, Independent Director
Richard Daniell, Executive Vice President - European Commercial
Mark Sabag, Executive Vice President, Chief Human Resources Officer and Global Communications and Brand
Ronit SatchiFainaro, Independent Director
Richard Lerner, Independent Director
Galia Maor, Independent Director
Janet Vergis, Independent Director
Carlo Notaristefani, CEO of Global Operations and President of Global Operations
JeanMichel Halfon, Statutory - independent director
Eli Shani, Ex Portfolio
Dipankar Bhattacharjee, Senior Vice President CFO Americas and Head of Finance Operations
Abbas Hussain, Independent Director
Yitzhak Peterburg, Director
Hafrun Fridriksdottir, Executive Vice President and Presidentident of Global Generics R&D
Perry Nisen, Independent Director
Isaac Abravanel, Group Executive Vice President Teva Corporate in Israel and Global Community Alliances, Director
David Stark, Executive Vice President, Chief Legal Officer
Amir Elstein, Vice Chairman of the Board
Dan Suesskind, Director
Arie Belldegrun, Independent Director
Richard Egosi, Chief Legal Officer and Group Executive VP
Andrew Weil, Chief Accounting Officer
Jean Halfon, Statutory - independent director
Sven Dethlefs, Executive Vice President - Global Marketing & Portfolio
Robert Koremans, President CEO-Global Specialty Medicines
Gerald Lieberman, Independent Director
Roberto Mignone, Independent Director
Rosemary Crane, Independent Director
Nechemia Peres, Independent Director
Roger Abravanel, Independent Director
Eyal Desheh, CFO and Group Executive VP
Gianfranco Nazzi, Executive Vice President - International Markets Commercial
Kare Schultz, CEO Pres
Iris BeckCodner, Group Executive Vice President - Corporate Marketing Excellence and Communication
Amir Weiss, VP Officer
Brendan OGrady, Executive Vice President - North America Commercial
Michael Hayden, President - Global Research and Development, Chief Scientific Officer
Gabrielle Sulzberger, Statutory Independent Director
Eric Drape, Executive Vice President - Global Operations
Erez Vigodman, CEO and President Director and Member of Fin. and Invesment Committee
Eliyahu Kalif, Chief Financial Officer, Executive Vice President, Director
Kathleen Veit, Global VP
Joseph Nitzani, Independent Director
Deborah Griffin, Chief Accounting Officer
Timothy Wright, Head - Business Development, Strategy and Innovation
Sigurdur Olafsson, President and CEO - Global Generic Medicines Group
Murray Goldberg, Independent Director
Dan Propper, Independent Director
Ory Slonim, Independent Director
Michael McClellan, Chief Financial Officer, Executive Vice President
Kevin Mannix, Vice President Head of Investor Relations
Kaare Schultz, President, Chief Executive Officer, Director
Sol Barer, Independent Chairman of the Board
Eli Kalif, Chief Financial Officer, Executive Vice President, Director

Teva Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Teva Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Teva Pharmaceutical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Teva Pharmaceutical's short interest history, or implied volatility extrapolated from Teva Pharmaceutical options trading.

Currently Active Assets on Macroaxis

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharmaceutical Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.

Complementary Tools for Teva Stock analysis

When running Teva Pharmaceutical's price analysis, check to measure Teva Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Teva Pharmaceutical is operating at the current time. Most of Teva Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Teva Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Teva Pharmaceutical's price. Additionally, you may evaluate how the addition of Teva Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Global Correlations
Find global opportunities by holding instruments from different markets
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Money Managers
Screen money managers from public funds and ETFs managed around the world
Please note, there is a significant difference between Teva Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.